Search results
Showing 16 to 30 of 34 results for ibs
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.
Evaluation of guidelines for the use of faecal calprotectin testing in primary care
to support a diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). The Department of...
What is the effect of relaxation and biofeedback therapies on [Irritable bowel syndrome] (IBS) symptoms and patient-related...
and tolerability of bile acid sequestrants among people with irritable bowel syndrome (IBS-D) or Crohn's disease without...
Refractory [Irritable bowel syndrome] (IBS):- What factors contribute to refractory IBS?
CG61/3 Question Refractory [Irritable bowel syndrome] (IBS):- What factors contribute to refractory IBS? Any...
management of [Irritable bowel syndrome] (IBS) symptoms, either as first-line therapies in primary care, or in the...
malabsorption in people with chronic diarrhoea diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without...
is a primary or secondary condition in people diagnosed with irritable bowel syndrome (IBS-D) or Crohn's disease without...
safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most...
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS54Show all sections
Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making
Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)
This evidence summary has been updated and replaced by NICE guideline CG61.